Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, ...

With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data ...

Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Dupilumab (Dupixent; Sanofi/Regeneron) has been approved to treat moderate to severe AD in children aged 6 months and older as well as in children who have asthma and eosinophilic esophagitis.

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Dupilumab is undergoing Priority Review by the FDA as an add-on maintenance therapy for adults with uncontrolled COPD and type 2 inflammation, with a target action date of June 27, 2024, according ...

Dupilumab is an effective and safe treatment option for patients with atopic dermatitis (AD) in real-life settings, including those with malignancy and other medical comorbidities, ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...